Evaluation Of Pre- And Post-operative Sequential Changes Of Serum P53 Autoantibodies In The Sera Of Patients With Ⅲ Stage Non-small-cell Lung Cancer

ObjectiveTo evaluate the value of detection sequential changing regularity of serum p53 antibodies combined with CEA and CYFRA21-1 after surgical resection and the relationship between serum p53 antibodies and clinicopathological characteristics in patients with non-small-cell lung cancer.MethodsThe serum p53 antibody, CEA and CYFRA21-1 levels were detected in 45 patients with lung cancer in 10 patients with benign pulmonary lesion and 30 healthy adults as control by enzyme linked immunosorbent assay (ELISA). Only those patients who were confirmed to â…¢ stage lung cancer by pathology were included in our study. The blood samples in lung cancer group were collected on the day before operation and on the 7th, 30th and 90th days postoperatively. 27 samples were collected on the 120th days and 19 samples were collected on the 180th days postoperatively.ResultsThe level and positive rate of serum p53 antibodies in patients with lung cancer were significantly higher than those in patients with benign pulmonary disease and normal individuals (P < 0.05), but there was no significant difference between patients with benign pulmonary disease and normal individuals (P>0.05). The level and positive rate of pre-operative serum p53 antibodies in patients with lung cancer were closely related to histopathologic type. The level of serum p53 antibodies decreased gradually in patients with lung cancer after radical removal of the cancer, and completely returned to the normal level around the 30th day after operation, but the level of serum p53 antibodies in patients with lung cancer didn't reduce to the normal level on the 30th day after palliative operation. It would increase again when tumor metastasis or recurrence developed. The level of serum Cyfra21-l decreased gradually in patients with lung cancer after radical removal of the cancer, and completely returned to the normal level around the 10th day after operation, but thelevel of serum Cyfra21-l in patients with lung cancer didn't reduce to the normal level on the 10th day after palliative operation. It would increase again when tumor metastasis or recurrence developed. The level of serum CEA decreased gradually in patients with lung cancer after radical removal of the cancer, and completely returned to the normal level around the 10th day after operation, the level of serum CEA in patients with lung cancer after palliative operation were in normal level.ConclusionThe results of the study indicate that serum Ab-anti-P53 are frequently present in â…¢ stage NSCLC patients. Anti-P53 antibodies emerging in blood serum in the subclinical phase of cancer development can reflect the mutation of P53 gene alteration. Serum p53Ab assessment is a simple and low-cost assay with a good specificity in â…¢ stage NSCLC patients, and it can be used at least in association with established tumor markers.